News

Ozempic and Mounjaro have new competitor as trial sees people lose 20% of body weight in one year
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...
Amgen experimental weight-loss drug needs lower dose to limit side effects
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
Amgen Shares Fall on Weight-Loss Drug Tummy Troubles
Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
Fierce Biotech2d
Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
STAT3d
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial
Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
Novo Nordisk (NVO), and Amgen (NASDAQ:AMGN) are scheduled to present major clinical trial readouts at the American Diabetes ...